Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HYDRO-SERP "50" vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
Hydrochlorothiazide 50 mg orally once daily.
250 mg orally twice daily
50-100 hours (prolonged in renal impairment; half-life up to 200 hours in severe renal disease)
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Hydrochlorothiazide is not extensively metabolized. Reserpine is metabolized primarily in the liver by CYP450 enzymes.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Renal (50-70% as unchanged drug and metabolites), biliary/fecal (20-30%)
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
90-96% (primarily to albumin and alpha1-acid glycoprotein)
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
200-400 L/kg (extremely large due to extensive tissue binding, especially in adrenergic nerve terminals)
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral: 40-50% (extensive first-pass metabolism)
70-90% (oral); 100% (IV).
Contraindicated in anuria. For GFR 30-60 m L/min: reduce dose to 25 mg daily. For GFR <30 m L/min: not recommended.
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B/C: use with caution; monitor electrolytes and renal function; reduce dose if needed.
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not typically recommended; safety and efficacy not established.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Initiate at 12.5-25 mg orally once daily; titrate cautiously; monitor electrolytes and renal function.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
None
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Electrolyte imbalance (especially hypokalemia),Sulfonamide allergy (hydrochlorothiazide),Mental depression (reserpine),Bradycardia and arrhythmias (reserpine)
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Anuria,Known sulfonamide allergy (hydrochlorothiazide),History of mental depression (reserpine),Active peptic ulcer or ulcerative colitis (reserpine),Electroconvulsive therapy (reserpine)
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-sodium foods (e.g., processed meats, canned soups) to prevent fluid retention and counteract antihypertensive effects. Avoid excessive potassium-rich foods (e.g., bananas, oranges, spinach) as thiazides cause potassium loss; however, reserpine may not affect potassium levels. Limit alcohol intake. Take with food or milk to reduce gastrointestinal upset.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
Hydrochlorothiazide: First trimester: Crosses placenta, risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse effects; limited human data, association with congenital anomalies not established. Second and third trimesters: May cause fetal or neonatal electrolyte disturbances, hypoglycemia, and decreased placental perfusion. Reserpine: First trimester: Animal studies show no teratogenic effects, human data insufficient. Second and third trimesters: May cause neonatal respiratory depression, bradycardia, hypothermia, and nasal congestion due to depletion of catecholamines.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Hydrochlorothiazide: Excreted into human milk in small amounts; M/P ratio approximately 0.2. Reserpine: Excreted into breast milk; M/P ratio not well established. Both are considered compatible with breastfeeding by most authorities, but use caution as reserpine may cause gastrointestinal disturbances, nasal congestion, and lethargy in the infant. Monitor infant for side effects.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Hydrochlorothiazide: Dose adjustment not typically required for pharmacokinetic changes, but use lowest effective dose due to risk of decreased placental perfusion. Reserpine: No specific dose adjustment recommended for pregnancy. Monitor for hypotension and avoid use near term to reduce neonatal adverse effects.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Hydrochlorothiazide 50 mg plus reserpine 0.125 mg. Monitor serum potassium and magnesium; hypokalemia increases digitalis toxicity risk. Reserpine may cause depression; avoid in patients with history of depression. Onset of antihypertensive effect is 3-6 hours. Use with caution in patients with renal impairment (Cr Cl <30 m L/min) as thiazides are ineffective.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,This drug may make you dizzy; avoid driving or operating machinery until you know how it affects you.,Reserpine can cause nasal congestion, drowsiness, or depression; contact your doctor if you experience mood changes.,Avoid alcohol as it may increase dizziness and drowsiness.,Stay hydrated but do not overhydrate; report excessive thirst, dry mouth, or muscle cramps.,Do not stop taking this medication abruptly as it may cause a rapid increase in blood pressure.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,This medication may increase your sensitivity to sunlight; use sunscreen and protective clothing.
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HYDRO-SERP "50" vs ALDOCLOR-250, answered by our medical review team.
HYDRO-SERP "50" is a Antihypertensive Combination that works by Hydrochlorothiazide inhibits the Na+-Cl- symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine depletes catecholamines (norepinephrine, dopamine) from peripheral sympathetic nerve endings, reducing vascular tone and heart rate.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HYDRO-SERP "50" and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HYDRO-SERP "50" is: Hydrochlorothiazide 50 mg orally once daily.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HYDRO-SERP "50" and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HYDRO-SERP "50" is classified as Category C. Hydrochlorothiazide: First trimester: Crosses placenta, risk of fetal or neonatal jaundice, thrombocytopenia, and possibly other adverse effects; limited human data, association wi. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.